Systemic lupus erythematosus and thrombosis

Thrombosis Journal

Fabio Marletto¹  Antonella Vaccarino¹  Mario Bazzan¹ 

[1] Haematology and Thrombosis Unit, CMID Department, San Giovanni Bosco Hospital, Piazza Donatore di Sangue 3, Turin, 10154, Italy

关键词: Risk factors;    Thrombosis;    Systemic lupus erythematosus;   

Others  :  1177398
DOI  :  10.1186/s12959-015-0043-3

 received in 2014-10-28, accepted in 2015-02-26,  发布年份 2015

【 摘 要 】

Systemic Lupus Erythematosus (SLE) is an acquired, multiorgan, autoimmune disease. Clinical presentation is extremely variable and heterogeneous. It has been shown that SLE itself is an independent risk factor for developing both arterial and venous thrombotic events since SLE patients have an Odds Ratio (OR) for thrombosis that varies depending on the clinical and laboratory characteristics of each study cohort. The risk of developing a thrombotic event is higher in this setting than in the general population and may further increase when associated with other risk factors, or in the presence of inherited or acquired pro-thrombotic abnormalities, or trigger events. In particular, a striking increase in the number of thrombotic events was observed when SLE was associated with antiphospholipid antibodies (aPL). The presence of aPLs has been described in about 50% of SLE patients, while about 20% of antiphospholipid syndrome (APS) patients have SLE. While APS patients (with or without an autoimmune disease) have been widely studied in the last years, fewer studies are available for SLE patients and thrombosis in the absence of APS. Although the available literature undoubtedly shows that SLE patients have a greater prevalence of thrombotic events as compared to healthy subjects, it is difficult to obtain a definite result from these studies because in some cases the study cohort was too small, in others it is due to the varied characteristics of the study population, or because of the different (and very copious) laboratory assays and methods that were used. When an SLE patient develops a thrombotic event, it is of great clinical relevance since it is potentially life-threatening. Moreover, it worsens the quality of life and is a clinical challenge for the clinician.

【 授权许可】

   
2015 Bazzan et al. ; licensee BioMed Central.

【 参考文献 】

• [1]Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al.: Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012, 4:2677-2686.
• [2]Yu C, Gershwin ME, Chang C: Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014, 48–49:10-13.
• [3]Stephenson JL, Shipman AR: The Systemic Lupus International Collaborating Clinics criteria have replaced the American College of Rheumatology guidelines for the diagnosis of systemic lupus erythematosus. Clin Exp Dermatol 2014, 39:431-432.
• [4]Fonseca AR, Gaspar-Elsas MI, Land MG, de Oliveira SK: Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology 2015, 54(2):241-7.
• [5]Inês L, Silva C, Galindo M, López-Longo FJ, Terroso G, Romão VC, et al. Classification of Systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. Arthritis Care Res 2015 Jan 7. doi: 10.1002/acr.22539. [Epub ahead of print]
• [6]Tsokos GC: Systemic Lupus Erythematosus. N Engl J Med 2011, 365:2110-2121.
• [7]Rahman A, Isenberg DA: Systemic Lupus Erythematosus N Engl J Med. 2008, 358:929-939.
• [8]Siegel M, Lee SL: The epidemiology of Systemic Lupus Erithematosus. Semin Arthritis Rheum 1973, 3:1-54.
• [9]Swigris JJ, Fischer A, Gillis J, Gilles J, Meehan RT, Brown KK: Pulmonary and thrombotic manifestations of Systemic Lupus Erythematosus. Chest 2008, 133:271-280.
• [10]Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al.: Morbidity and mortality in systemic lupus erythematosus during a 10 year period : a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 2003, 82:299-308.
• [11]Pons Estel GI, Alarcon GS, Scofield L, Reinlib L, Cooper GS: Understanding the epidemiology and progression of Systemic Lupus Erythematosus. Semin Arthritis Rheum 2010, 39:257-268.
• [12]Bertoli AM, Fernández M, McGwin G Jr, Alarcón GS, Tan FK, Reveille JD, et al.: Systemic lupus erythematosus in a multiethnic US color. XXXIII: clinical (corrected) features, course and outcome in patients with late-onset disease. Arthritis Rheum 2006, 54:1580-1587.
• [13]Erkan D: Lupus and thrombosis. J Rheumatol 2006, 33:1715-1717.
• [14]Les I, Ruiiz-Irastorza G, Kamashta MA: Intensity and duration of anticoagulant therapy in antiphospholipid syndrome. Sem Thromb Haemost 2012, 38:339-347.
• [15]Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR: Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) 1983, 287:1021-1023.
• [16]Hughes GRV: Thrombosis, aborption, cerebral disease and the lupus anticoagulant. BMJ 1983, 287:1088-1089.
• [17]Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
• [18]Pengo V, Tripodi A, Reber G, Ortel TL, Galli M, De Groot PG, et al.: Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7(10):1737-40.
• [19]Bazzan M, Vaccarino A, Stella S, Bertero MT, Carignola R, Montaruli B, et al.: Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 2013, 12(8):823-831.
• [20]Bertero MT, Bazzan M, Carignola R, Montaruli B, Silvestro E, Sciascia S, et al.: Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. Lupus 2012, 21(7):806-918.
• [21]Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al.: Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8(2):237-242.
• [22]Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al.: Morbidity and mortality in the antiphospholipid syndrome during 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009, 68:1428-1432.
• [23]Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014 Jan 24doi:10.1136/annrheumdis-2013-204838. [Epub ahead of print].
• [24]Stojan G, Petri M: Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol 2013, 62(3):255-62.
• [25]Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60 :221-225.
• [26]Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al.: Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
• [27]Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al.: Traditional Framing-ham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337.
• [28]Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, et al.: Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012, 14:R46. BioMed Central Full Text
• [29]Gustafsson JT, Svenungsson E: Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 2014, 47(2):67-76.
• [30]Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
• [31]Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
• [32]Gustafsson J, Gunnarsson I, Börjesson O, Pettersson S, Möller S, Fei GZ, et al.: Predictors of the first cardiovascular event in patients with systemic lupus erythematosus – a prospective cohort study. Arthritis Res Ther 2009, 11:R186. BioMed Central Full Text
• [33]Hillen T, Nieczaj R, Münzberg H, Schaub R, Borchelt M, Steinhagen-Thiessen E: Carotid atherosclerosis, vascular risk profile and mortality in a population-based sample of functionally healthy elderly subjects: the Berlin ageing study. J Intern Med 2000, 247:679-688.
• [34]Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 2007, 145:408-415.
• [35]Magder LS, Petri M: Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012, 176:708-719.
• [36]Ravenell RL, Kamen DL, Spence JD, Hollis BW, Fleury TJ, Janech MG, et al.: Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. Am J Med Sci 2012, 344:268-273.
• [37]Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, et al.: Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412-3419.
• [38]Urowitz MB, Gladman DD, Tom BD, Ibañez D, Farewell VT: Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol 2008, 35:2152-2158.
• [39]McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, et al.: Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2428-2437.
• [40]Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, et al.: Impaied serum Cholesterol efflux capacity in rheumatoid arthritis and sistemi lupus erythematosus. Ann Reum Dis 2014, 73:609-615.
• [41]Frostegård J, Svenungsson E, Wu R, Gunnarsson I, Lundberg IE, Klareskog L, et al.: Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005, 52:192-200.
• [42]Spiel AO, Gilbert JC, Jilma B: Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008, 117:1449-1459.
• [43]Knight JS, Carmona-Rivera C, Kaplan M: Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol 2012, 3:380.
• [44]Lahoute C, Herbin O, Mallat Z, Tedgui A: Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011, 8:348-358.
• [45]Caligiuri G, Nicoletti A, Poirier B, Hansson GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002, 109:745-753.
• [46]Ambrosino P, Lupoli R, DiMinno A, Lervolino S, Peluso MND DiMinno R: Markers of gardiovascular risk in patients with antiphospholipid syndrome: meta-analysis of literatute studies. Ann Med 2014, 46:693-672.
• [47]Ballocca F, D'Ascenzo F, Moretti C, Omedè P, Cerrato E, Barbero U, Abbate A, Bertero MT, Zoccai GB, Gaita F : Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2014; [Epub ahead of print]
• [48]Kaiser G, R Tang LF, Taylor KE, Sterba K, Nititham J, Brown EE, et al.: A polymorphism in TLR2 is associated with arterial thrombosis in a multiethnic population of patients with systemic lupus erythematosus. Arthritis. Rheumatol 2014, 66:1882-1887.
• [49]Bruce IN: 44: “Not only….but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005, 44:1492-1502.
• [50]Gorman C, Isemberg D: Atherosclerosis in lupus. Rheumatology 2004, 43:943-945.
• [51]Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071-1077.
• [52]Tazi Mezalek Z, Harmouche H, Ammouri W, Maamar M, Adnaoui M, Cacoub P: Atherosclerosis in systemic lupus erythematosus. Presse Med 2014, 43(10 1):1034-47.
• [53]Costedoat-Chalumeau N, Dunoguè B, Morel N, Le Guern V, Guettrot-Imbert G: Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014, 43(6):167-180.
• [54]Knight JS, Kaplan MJ: Cardiovascular disease in lupus: insights and updates. Curr Opin Rheumatol 2013, 25(5):597-605.
• [55]Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
• [56]Yen YC, Weng SF, Chen HA, Lin YS: Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study. Br J Ophthalmol 2013, 97(9):1192-1196.
• [57]Zaldívar-alcántara H, Herrera-jiménez LE, Dehesa-lópez E, Correa-rotter R: Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropatic. Rev Invest Clin 2013, 65(3):199-208.
• [58]Chung WS, Lin CL, Chang SN, Lu CC, Kao CH: Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost 2014, 12(4):452-8.
• [59]Bengtsson C, Ohman ML, Nived O, Rantapää Dahlqvist S: Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study. Lupus 2012, 21(4):452-9.
• [60]Baronaite Hansen R, Jacobsen S: Infections Increase Risk of Arterial and Venous Thromboses in Danish Patients with Systemic Lupus Erythematosus: 5102 Patient-years of Followup. J Rheumatol 2014, 41(9):1817-22.
• [61]Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al.: Prevention of VTE in Nonsurgical patients. CHEST 2012, 141(2):Suppl:e 195S-226S.
• [62]Caprini JA: Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010, 199(1 Suppl):S3-10.
• [63]Rogers SO Jr, Kilaru RK, Hosokawa P, Henderson WG, Zinner MJ, Khuri SF: Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007, 204(6):1211-21.
• [64]Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al.: A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010, 8(11):2450-2457.
• [65]Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al.: Antithrombotic therapy for VTE disease. CHEST 2012, 141(2):419S-494S.
• [66]Bazzan M, Vaccarino A: Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies: only in selected, high risk patients. Intern Emerg Med 2009, 4(1):61-2.
• [67]Metjian A, Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis? Hematology Am Soc Hematol Educ Program. 2009;247–9.
• [68]Arnaud L, Mathian A, Ruffatti A, Erkan D, Tektonidou M, Cervera R, et al.: Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014, 13(3):281-91.
• [69]Bertero MT: Primary prevention in antiphospholipid antibody carriers. Lupus 2012, 21(7):751-4.
• [70]Lateef A, Petri M : Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol. 2013
• [71]Clowse ME, Jamison M, Myers E, James AH: A National study of the complication of lupus in pregnancy. Am J Obstet Gynecol 2008, 99:121-126.
• [72]Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, et al.: Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64(7):2311-8.
• [73]Del Ros T, Ruffatti A, Visentin MS, Tonello M, Calligaro A, Favaro M, et al.: Treatment of 139 pregnancies in antiphospholipid positive women not fullifilling criteria for antiphospholipid syndrome: a retrospective study. J Rheumatol 2013, 40:425-429.
• [74]Empson M, Lassere M, Craig J, Scott J: Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005
• [75]Mak A, Cheung MW, Cheak AA, Ho RC: Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patient with recurrent pregnancy loss and positive antiphospholipid antibodies: a meta analysis of randomized controlled trials and meta regression. Rheumatology 2010, 49:281-288.
• [76]Giannubilo SR, Tranquilli AL: Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombofilia. Curr Med Chem 2012, 19(27):4562-4571.
• [77]Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO: VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians CHEST 2012, 141(2 Suppl):e691S-736S.
• [78]Sammaritano L: Contraception in patients with sistemic lupus erythematosus and antiphospholIpid syndrome. Lupus 2014, 23:1242-1245.
• [79]Nayer A, Ortega LM: Catastrophic antiphospholipid syndrome: a critical review. J Nephropathol 2014, 3(1):9-17.
• [80]Asherson RA, Espinosa G, Cervera R, Font J, Reverter JC: Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002, 8(3):157-65.
• [81]Tektonidou MG, Sotsiou F, Moutsopoulos HM: Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 2008, 35(10):1983-8.
• [82]Rangel ML, Alghamdi I, Contreras G, Harrington T, Thomas DB, Barisoni L, et al.: Catastrophic Antiphospholipid Syndrome with Concurrent Thrombotic and Hemorrhagic Manifestations. Lupus 2013, 22(8):855-64.
• [83]Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado M: Catastrophic antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol 2012, 26(4):535-41.
• [84]Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al.: European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006, 54(8):2568-76.